Business
Codexis Announces License Agreement with Roche for Enzyme Used in Next Generation Sequencing
REDWOOD CITY, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces a license agreement to
About this update from Codexis, Inc.
[{"type":"text","content":"REDWOOD CITY, Calif., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces a license agreement to provide Roche with Codexis’ EvoT4TM DNA ligase high-performance molecular diagnostic enzyme. This enzyme was developed using Codexis’ proprietary CodeEvolver® protein engineering platform and is expected to be incorporated into Roche’s next generation sequencing (NGS) library preparation kits and other sequencing products. The royalty bearing license grants Roche worldwide rights to include the EvoT4TM DNA ligase in its nucleic acid sequencing products and workflows.\n Library preparation is a critical first step in the NGS workflow and involves modifying nucleic acid samples using a coordinated series of enzymatic reactions to produce libraries of DNA fragments for high-throughput sequencing. The EvoT4TM DNA ligase was developed to improve the efficiency and speed of adapter ligation for challenging and low-input DNA samples, thereby improving NGS sensitivity and accuracy – both important attributes for sequencing applications. “We are very excited to license our first product targeting this market to Roche Sequencing Solutions. This deal underscores our belief in genomic sequencing as an attractive commercial target for our company, and we look forward to future successful introductions of additional CodeEvolver®-derived innovations in this and other Life Science applications,” said Codexis CEO and President John Nicols. About Codexis, Inc. Codexis is a leading protein engineering company that applies its proprietary CodeEvolver® technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis’ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes. For more information, see www.codexis.com Forward-Looking Statements To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of manageme...